share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  05/02 08:03

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc., a Texas-based company trading under the symbol MGRX on the Nasdaq Stock Market, has been granted a 180-day extension until October 24, 2024, to meet the Nasdaq's minimum bid price requirement. The company had previously been notified of non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Mangoceuticals reported stockholders' equity of $1,354,821 in the quarter ended September 30, 2023, which was below the Nasdaq's minimum requirement of $2,500,000. However, following certain transactions, the company believes it has regained compliance with the stockholders' equity rule. The company has also been advised that failure to demonstrate compliance upon filing its next periodic report may lead to delisting. To address the minimum bid price requirement, Mangoceuticals may consider a reverse...Show More
Mangoceuticals, Inc., a Texas-based company trading under the symbol MGRX on the Nasdaq Stock Market, has been granted a 180-day extension until October 24, 2024, to meet the Nasdaq's minimum bid price requirement. The company had previously been notified of non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Mangoceuticals reported stockholders' equity of $1,354,821 in the quarter ended September 30, 2023, which was below the Nasdaq's minimum requirement of $2,500,000. However, following certain transactions, the company believes it has regained compliance with the stockholders' equity rule. The company has also been advised that failure to demonstrate compliance upon filing its next periodic report may lead to delisting. To address the minimum bid price requirement, Mangoceuticals may consider a reverse stock split, which was previously approved by shareholders. The company's common stock will be subject to delisting if compliance is not regained within the extension period. Additionally, Mangoceuticals has corrected errors in a previously filed Certificate of Designations regarding its Series C Preferred Stock and has announced the date for its 2024 Annual Meeting of Stockholders.
總部位於德克薩斯州的Mangoceuticals, Inc. 是一家在納斯達克股票市場上交易代碼爲MGRX的公司,已獲准將期限延長180天至2024年10月24日,以滿足納斯達克的最低出價要求。該公司此前曾被告知不遵守納斯達克的最低出價和股東權益要求。Mangoceuticals報告稱,截至2023年9月30日的季度股東權益爲1,354,821美元,低於納斯達克規定的250萬美元的最低要求。但是,在進行某些交易之後,該公司認爲已經恢復了對股東權益規則的遵守。該公司還被告知,在提交下一次定期報告時未能證明其合規性可能會導致退市。爲了滿足最低出價要求,Mangoceuticals可能會考慮反向股票拆分,該拆分此前已獲得股東批准。如果在延長期內沒有恢復合規性,該公司的普通股將被退市。此外,Mangoceuticals更正了先前提交的有關其C系列優先股的指定證書中的錯誤,並宣佈了其2024年年度股東大會的日期。
總部位於德克薩斯州的Mangoceuticals, Inc. 是一家在納斯達克股票市場上交易代碼爲MGRX的公司,已獲准將期限延長180天至2024年10月24日,以滿足納斯達克的最低出價要求。該公司此前曾被告知不遵守納斯達克的最低出價和股東權益要求。Mangoceuticals報告稱,截至2023年9月30日的季度股東權益爲1,354,821美元,低於納斯達克規定的250萬美元的最低要求。但是,在進行某些交易之後,該公司認爲已經恢復了對股東權益規則的遵守。該公司還被告知,在提交下一次定期報告時未能證明其合規性可能會導致退市。爲了滿足最低出價要求,Mangoceuticals可能會考慮反向股票拆分,該拆分此前已獲得股東批准。如果在延長期內沒有恢復合規性,該公司的普通股將被退市。此外,Mangoceuticals更正了先前提交的有關其C系列優先股的指定證書中的錯誤,並宣佈了其2024年年度股東大會的日期。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息